Mission Bay Capital, LLC, is an independent seed-stage venture firm focused on making pivotal, investments in bioscience companies emerging from the University of California. Founded in August 2009, Mission Bay Capital combines the rich knowledge and navigation skills of QB3 executives – Drs. Regis Kelly and Douglas Crawford – with the experience and proven success of a renowned investment advisory committee led by Brook Byers and John Wadsworth. Mission Bay Capital is fueling breakthrough bioscience technologies to meet society’s challenges while also helping to boost the California economy.
|Effector Therapeutics||5/2013||Series A||$45M||7|
|Principia BioPharma||10/2012||Series A||$12.5M||5|
|Calithera Biosciences||7/2010||Series A||$40M||5|
|Redwood Bioscience||4/2010||Venture Round||$300k||1|
|California Institute for Quantitative Biosciences||10/2009||Seed||$7.5M||1|